[The major response of metastatic kidney cancer to the combination of oxaliplatin, 5-fluorouracil and folinic acid (FOX-FOL)].
B
B
Chauffert
B
B
Bonnotte
G
G
Chvetzoff
M
M
Flesch
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D000931:Antidotes / Q000008:administration & dosage*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D002955:Leucovorin / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000556:secondary*
D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil
Réponse majeure d'un cancer du rein métastatique à l'association oxaliplatine, 5-fluorouracile et acide L-folinique (FOL-FOX).